Litcius/Paper detail

Immunothrombosis in severe COVID-19

Daigo Nakazawa, Akihiro Ishizu

2020EBioMedicine32 citationsDOIOpen Access PDF

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread all over the world immediately after the first patient infected with this virus was discovered in Wuhan, China, in December 2019. The World Health Organization has named the disease induced by SARS-CoV-2 as coronavirus disease 2019 (COVID-19). Although COVID-19 was initially recognized as an acute respiratory distress syndrome, recent studies have revealed that coagulation disorders and thrombotic events contribute to its high mortality It has been demonstrated that SARS-CoV-2 infection induces vascular endothelial injury, resulting from coagulation However, the pathological feature of thrombus induced by SARS-CoV-2 remains incompletely understood.

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineScopusDiseaseImmunologyMEDLINEBiologyInfectious disease (medical specialty)BiochemistryCOVID-19 Clinical Research StudiesVenous Thromboembolism Diagnosis and ManagementInflammasome and immune disorders
Immunothrombosis in severe COVID-19 | Litcius